• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
CONCLUSIONS: Anlotinib combined with temozolomide is efficacious and tolerated in recurrent GBM patients.PMID:37477938 | DOI:10.1158/1078-0432.CCR-23-0388
Source: Clinical Cancer Research - July 21, 2023 Category: Cancer & Oncology Authors: Qingsheng Xu Kaiyuan Huang Xiangqi Meng Yuxiang Weng Luyuan Zhang Linghao Bu Xiujue Zheng Jinquan Cai Renya Zhan Qun Chen Source Type: research

NAMPT as a Dedifferentiation-Inducer Gene: NAD+ as Core Axis for Glioma Cancer Stem-Like Cells Maintenance
Conclusion and Perspectives Gliomas are the most prevalent primary brain cancer in adults and include a broad category of tumors including astrocytoma, oligodendroglioma, and GBM. Regardless of tumor aggressiveness, malignancy, and infiltration, these glia-derived tumors rarely exceed a median survival time of 12–14 months. Driven by the infiltrative nature of these tumors, the clinical approach is difficult and relapses often occur with fatal consequences. These unsuccessful attempts to control glioma's fate have fostered research looking for more effective therapies. (GSCs) are a small subset of CD133&#...
Source: Frontiers in Oncology - May 2, 2019 Category: Cancer & Oncology Source Type: research

Stroke-like migraine attacks in long term survivors of high grade glioma. (P1.174)
Conclusions:Stroke-like migraine attacks are difficult to treat and the pathophysiology is unknown. With more sophisticated imaging techniques, a better understanding of this phenomenon will aid in the treatment and prophylaxis of the syndrome with a goal of improving quality of life for this small but slowly growing population.Disclosure: Dr. New has nothing to disclose. Dr. Mirza has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: New, P., Mirza, H. Tags: Neuro-oncology: Gliomas I Source Type: research

Tumor Treating Fields (TTF) with Triple Chemotherapy for Recurrent Glioblastoma (P1.177)
Conclusions:Therapies with TTF plus TBC demonstrates superior OS benefit for recurrent GBM with moderate, but manageable side effects. A prospective study of TTF plus TBC for recurrent GBM is warranted.Study Supported by: Dr. Marnie Rose FoundationDisclosure: Dr. Zhu has received personal compensation for activities with Novocure, and Prime Oncology. Dr. Zhu has received research support from Novocure, Inc., Five Prime Therapeutics, Immuno-Cellular Inc., DEKK-TEC. Dr. Lu has nothing to disclose. Dr. Rao has nothing to disclose. Dr. Zhu has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Zhu, J.-J., Lu, G., Rao, M., Zhu, P. Tags: Neuro-oncology: Gliomas I Source Type: research

P08.46 Rechallenge with bevacizumab in a long-term survivor with glioblastoma
The prognosis of patients with glioblastoma multiforme (GBM, WHO grade IV), the most common primary brain tumor in adults, is generally poor with median survival of less than one year in untreated patients and approximately 15 months following standard of care therapy. However, 10 % survival at 5 years was observed in a randomized phase III study. At GBM recurrence, the addition of bevacizumab (BEV), a humanized monoclonal antibody against circulating vascular endothelial growth factor (VEGF), resulted in a 3–4 month prolongation of progression-free survival (PFS) without improving overall survival (OS...
Source: Neuro-Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Koeppen, S., Hense, J. Tags: P08 Glioblastom and Anaplastic gliomas Source Type: research

Temozolomide in low-grade gliomas: living longer and better
Low-grade gliomas (LGGs) account for about a third of gliomas overall and 15% of all primary brain tumours. In adults, the majority of LGGs are WHO Grade II astrocytomas and oligodendrogliomas, which differ in molecular fingerprints and median survival, but share a propensity to malignant transformation after a number of years. Up to 90% of LGGs present with seizures and epilepsy may be the only symptom for many years, significantly impairing quality of life and impacting on social and professional functioning.1 In about 50% of cases, the epilepsy is refractory to antiepileptic drugs (AEDs) with a quarter of patients requi...
Source: Journal of Neurology, Neurosurgery and Psychiatry - March 13, 2015 Category: Neurosurgery Authors: Rees, J. Tags: Immunology (including allergy), Epilepsy and seizures, Neurooncology, Stroke, CNS cancer, Radiology, Surgical oncology Editorial commentaries Source Type: research

Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide
Conclusions TMZ may contribute to an important reduction in seizure frequency in patients with LGG. Seizure reduction following TMZ treatment has prognostic significance and may serve as an important clinical outcome measure in patients with LGG.
Source: Journal of Neurology, Neurosurgery and Psychiatry - March 13, 2015 Category: Neurosurgery Authors: Koekkoek, J. A. F., Dirven, L., Heimans, J. J., Postma, T. J., Vos, M. J., Reijneveld, J. C., Taphoorn, M. J. B. Tags: Epilepsy and seizures, Neurooncology, Stroke, CNS cancer Neuro-oncology Source Type: research